Come up with a name for your new list and we'll add to it:
Decimmune Therapeutics raised a round of funding on September 28, 2010. Investors include
National Institutes of Health.
DecImmune Therapeutics is developing a novel monoclonal antibody, DeciMab, aimed at preventing tissue damage and preserving organ function in a range of vascular inflammatory diseases. The company's a…